JP2006526608A - Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド - Google Patents

Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド Download PDF

Info

Publication number
JP2006526608A
JP2006526608A JP2006508422A JP2006508422A JP2006526608A JP 2006526608 A JP2006526608 A JP 2006526608A JP 2006508422 A JP2006508422 A JP 2006508422A JP 2006508422 A JP2006508422 A JP 2006508422A JP 2006526608 A JP2006526608 A JP 2006526608A
Authority
JP
Japan
Prior art keywords
benzofuran
methoxy
carboxylic acid
tetrazol
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006508422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526608A5 (enExample
Inventor
ロッコ・ディーン・ゴグリオッティ
ヘレン・ツェンウィ・リー
カレン・エレイン・セクストン
メリーン・ヴィスニック
Original Assignee
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー filed Critical ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー
Publication of JP2006526608A publication Critical patent/JP2006526608A/ja
Publication of JP2006526608A5 publication Critical patent/JP2006526608A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006508422A 2003-06-05 2004-05-24 Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド Abandoned JP2006526608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47625103P 2003-06-05 2003-06-05
PCT/IB2004/001788 WO2004108709A1 (en) 2003-06-05 2004-05-24 Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents

Publications (2)

Publication Number Publication Date
JP2006526608A true JP2006526608A (ja) 2006-11-24
JP2006526608A5 JP2006526608A5 (enExample) 2007-09-06

Family

ID=33511768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508422A Abandoned JP2006526608A (ja) 2003-06-05 2004-05-24 Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド

Country Status (7)

Country Link
US (1) US20050020631A1 (enExample)
EP (1) EP1644364A1 (enExample)
JP (1) JP2006526608A (enExample)
BR (1) BRPI0411098A (enExample)
CA (1) CA2527934A1 (enExample)
MX (1) MXPA05012894A (enExample)
WO (1) WO2004108709A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US8906894B1 (en) * 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
FR2862646B1 (fr) * 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー 固形腫瘍の治療方法
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
EP2492269A4 (en) 2009-10-19 2013-08-07 Taisho Pharmaceutical Co Ltd aminothiazole
PL223225B1 (pl) * 2012-02-21 2016-10-31 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk Halogenopochodne benzo[b]furanów, ewentualnie w postaci farmaceutycznie dopuszczalnej soli oraz zastosowanie halogenopochodnych benzo[b]furanów
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
MX2023014819A (es) * 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.
CN117813293A (zh) * 2021-06-14 2024-04-02 蝎子疗法股份有限公司 可用于治疗癌症的脲衍生物
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
TW202600543A (zh) * 2024-03-11 2026-01-01 大陸商長春金賽藥業有限責任公司 ＰＩ３Ｋα抑制劑化合物、藥物組合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954748A (en) * 1968-07-29 1976-05-04 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France 3-Alkoxy-thianapthene-2-carboxamides
US4703053A (en) * 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
IE58555B1 (en) * 1984-12-10 1993-10-06 Warner Almbert Company Novel benzothiophenes and benzofurans having antiallergy activity
US4800211A (en) * 1986-08-18 1989-01-24 Merck & Co., Inc. 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors
US4767776A (en) * 1987-02-20 1988-08-30 Warner-Lambert Company N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents
US4764525A (en) * 1987-02-25 1988-08-16 Warner-Lambert Company N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents
US4931459A (en) * 1987-07-14 1990-06-05 Warner-Lambert Company Method for treating acute respirator distress syndrome
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
AU8641991A (en) * 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5208253A (en) * 1992-02-24 1993-05-04 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo(b) thiophene-2-carboxamides as inhibitors of cell adhesion
US5426113A (en) * 1994-04-08 1995-06-20 Warner-Lambert Company Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds
HRP950288A2 (en) * 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
WO1997009056A1 (fr) * 1995-09-07 1997-03-13 L'oreal Extrait d'iridacees et compositions le contenant
DE19911165B4 (de) * 1999-03-12 2008-03-13 Bayer Cropscience Ag Entlaubungsmittel
US6444613B1 (en) * 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
ATE363471T1 (de) * 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen

Also Published As

Publication number Publication date
EP1644364A1 (en) 2006-04-12
US20050020631A1 (en) 2005-01-27
CA2527934A1 (en) 2004-12-16
WO2004108709A1 (en) 2004-12-16
MXPA05012894A (es) 2006-02-22
BRPI0411098A (pt) 2006-07-18

Similar Documents

Publication Publication Date Title
US20050020631A1 (en) 3-Substituted benzofurans as therapeutic agents
US20050020630A1 (en) Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
EP1636213B1 (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
US7074814B2 (en) 3-substituted indoles and derivatives thereof as therapeutic agents
JP2006512357A (ja) Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
EP1636212B1 (en) Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
JP4908210B2 (ja) Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
US20080255162A1 (en) Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
US20040248953A1 (en) 3-Arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents
JP2007504209A (ja) ＰＩ３Ｋ阻害活性を有する治療薬としてのハロゲン置換ベンゾ（ｂ）チオフェン類
JP2007509924A (ja) ホスホイノシチド−３−キナーゼ（ｐｉ３ｋ）阻害剤としてのピリミジン
MXPA05013056A (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070703

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20070704